Pacira BioSciences, Inc. (NASDAQ:PCRX) Insider Jonathan Slonin Sells 879 Shares

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) insider Jonathan Slonin sold 879 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $18.40, for a total transaction of $16,173.60. Following the transaction, the insider now directly owns 93,444 shares of the company's stock, valued at $1,719,369.60. The trade was a 0.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Pacira BioSciences Stock Performance

Pacira BioSciences stock traded up $0.23 during midday trading on Monday, hitting $18.63. 581,938 shares of the company's stock were exchanged, compared to its average volume of 547,046. The firm's 50 day simple moving average is $18.06 and its 200 day simple moving average is $17.92. Pacira BioSciences, Inc. has a 12-month low of $11.16 and a 12-month high of $35.95. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The stock has a market cap of $860.20 million, a price-to-earnings ratio of -9.18 and a beta of 0.76.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Royal Bank of Canada raised their price target on Pacira BioSciences from $15.00 to $16.00 and gave the stock a "sector perform" rating in a research report on Thursday, November 7th. Jefferies Financial Group boosted their price target on shares of Pacira BioSciences from $15.00 to $18.00 and gave the stock a "buy" rating in a research note on Tuesday, September 24th. HC Wainwright restated a "buy" rating and issued a $39.00 price objective on shares of Pacira BioSciences in a report on Wednesday, December 4th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price objective on shares of Pacira BioSciences in a research report on Friday, November 8th. Finally, Barclays decreased their target price on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating for the company in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $23.50.

Hedge Funds Weigh In On Pacira BioSciences

Institutional investors have recently added to or reduced their stakes in the stock. CWM LLC grew its stake in shares of Pacira BioSciences by 713.6% in the 3rd quarter. CWM LLC now owns 6,517 shares of the company's stock valued at $98,000 after purchasing an additional 5,716 shares during the last quarter. Virtus Investment Advisers Inc. purchased a new position in Pacira BioSciences during the 3rd quarter worth $98,000. Quest Partners LLC acquired a new stake in shares of Pacira BioSciences in the 2nd quarter worth $113,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Pacira BioSciences by 62.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company's stock valued at $134,000 after acquiring an additional 3,404 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Pacira BioSciences during the second quarter worth about $140,000. Institutional investors and hedge funds own 99.73% of the company's stock.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.